Inventor · disambiguated record
Patricia Culp
Also filed as: CULP PATRICIA · CULP PATRICIA A
13 granted patents·14 pending applications·33 citations·filing 2004–2025
88Inventor score
Files withALECTOR LLC16PROTEIN DESIGN LABS INC3TAKEDA PHARMACEUTICALS CO3ABBVIE BIOTHERAPEUTICS INC2CULP PATRICIA1
Top patents by PatentIndex Score
27 records- 0193US10711062B2Anti-CD33 antibodies and methods of use thereofALECTOR LLC·Filed 2018·Granted Jul 14, 2020·7 cites·77 claims
- 0292US10233258B2Bispecific binding proteins that bind CD40 and mesothelinABBVIE BIOTHERAPEUTICS INC·Filed 2018·Granted Mar 19, 2019·16 cites·10 claims
- 0390US11965023B2Anti-Siglec-5 antibodies and methods of use thereofALECTOR LLC·Filed 2022·Granted Apr 23, 2024·1 cites·32 claims
- 0490US11254743B2Anti-CD33 antibodies and methods of use thereofALECTOR LLC·Filed 2020·Granted Feb 22, 2022·2 cites·20 claims
- 0588US12258410B2Anti-SIRPα antibodies and methods of use thereofALECTOR LLC·Filed 2024·Granted Mar 25, 2025·0 cites·76 claims
- 0682US11319373B2Anti-SIRPA antibodies and methods of use thereofALECTOR LLC·Filed 2019·Granted May 3, 2022·1 cites·83 claims
- 0779US12247073B2Anti-CD33 antibodies and methods of use thereofALECTOR LLC·Filed 2019·Granted Mar 11, 2025·1 cites·84 claims
- 0879US11976119B2Anti-SIRPa antibodies and methods of use thereofALECTOR LLC·Filed 2022·Granted May 7, 2024·0 cites·91 claims
- 0978US11359014B2Anti-siglec-5 antibodies and methods of use thereofALECTOR LLC·Filed 2018·Granted Jun 14, 2022·2 cites·25 claims
- 1076US2025026827A1Anti-SIRP-Beta1 Antibodies and Methods of Use ThereofALECTOR LLC·Filed 2024·Application pending·0 cites
- 1175US2025179189A1Anti-SIRPa Antibodies and Methods of Use ThereofALECTOR LLC·Filed 2025·Application pending·0 cites
- 1273US12258398B2Anti-Siglec-5 antibodies and methods of use thereofALECTOR LLC·Filed 2019·Granted Mar 25, 2025·1 cites·34 claims
- 1371US9056908B2Therapeutic use of anti-tweak receptor antibodiesCULP PATRICIA·Filed 2008·Granted Jun 16, 2015·2 cites·21 claims
- 1471US2022162309A1Anti-cd33 antibodies and methods of use thereofALECTOR LLC·Filed 2022·Application pending·0 cites
- 1568US2010074841A1Compositions Against Cancer Antigen LIV-1 and Uses ThereofFACET BIOTECH CORP·Filed 2009·Application pending·0 cites
- 1668US2008175839A1Compositions Against Cancer Antigen LIV-1 and Uses ThereofPROTEIN DESIGN LABS INC·Filed 2007·Application pending·0 cites
- 1764US2008171039A1Compositions Against Cancer Antigen Liv-1 and Uses ThereofPROTEIN DESIGN LABS INC·Filed 2007·Application pending·0 cites
- 1862US2004141983A1Compositions against cancer antigen LIV-1 and uses thereofPROTEIN DESIGN LABS INC·Filed 2004·Application pending·0 cites
- 1962US2025270319A1Anti-cd33 antibodies and methods of use thereofALECTOR LLC·Filed 2025·Application pending·0 cites
- 2061US12227568B2Anti-Siglec-7 antibodies and methods of use thereofALECTOR LLC·Filed 2019·Granted Feb 18, 2025·0 cites·38 claims
- 2159US2025145709A1Anti-siglec-7 antibodies and methods of use thereofALECTOR LLC·Filed 2025·Application pending·0 cites
- 2258US12060422B2Anti-SIRP-Beta1 antibodies and methods of use thereofALECTOR LLC·Filed 2019·Granted Aug 13, 2024·0 cites·23 claims
- 2357US2025304686A1Conditionally bispecific binding proteinsTAKEDA PHARMACEUTICALS CO·Filed 2021·Application pending·0 cites
- 2457US2023340159A1Constrained conditionally activated binding proteinsTAKEDA PHARMACEUTICAL COMPAMY LTD·Filed 2023·Application pending·0 cites
- 2557US2023312715A1Constrained conditionally activated binding protein constructs with human serum albumin domainsTAKEDA PHARMACEUTICALS CO·Filed 2021·Application pending·0 cites
- 2652US2024026011A1Constrained conditionally activated binding proteinsTAKEDA PHARMACEUTICALS CO·Filed 2021·Application pending·0 cites
- 2746US2017342169A1Bispecific binding proteinsABBVIE BIOTHERAPEUTICS INC·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Patricia Culp files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →